Platinums sensitize human epithelial tumor cells to lymphotoxin α by inhibiting NFκB-dependent transcription

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1409-1416

  Shen, Yijun ^a   Wang, Jing ^a   Yang, Tong ^a   Li, Yuhong ^b   Jiang, Wenqi ^b   Guan, Zhongzhen ^b   Wang, Zheng ^a   Tan, Jingwei ^a   Wu, Jinsong ^a   Li, Gang ^a   Xu, Qing ^c   Wu, Fang ^a   Wang, Luochun ^a   Liu, Yanjun ^a  

^a Shanghai Fudan Zhangjiang Bio pharmaceutical Co Ltd   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Chemotherapy; Combined therapy; Epithelial tumor cells; Lymphotoxin ; NF B; Platinums; Sensitization

Indexed keywords

CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; MITOMYCIN; NAVELBINE; OXALIPLATIN; PLATINUM COMPLEX; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; EPITHELIUM TUMOR; HUMAN; RNA TRANSCRIPTION; TUMOR CELL; TUMOR REGRESSION;

EID: 52149117578     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ruggiero V, Antonelli G, Gentile M, Conciatori G, Dianzani F. Comparative study on the antiviral activity of tumor necrosis factor (TNF)alpha, lymphotoxin/TNFbeta and IL-1 in WISH cells. Immunol Lett 1989; 21:165-9.
2. Waterer GW, Wunderink RG. Science review: Genetic variability in the systemic inflammatory response. Crit Care 2003; 7:308-14.
3. Denisov AA, Nikolaeva OG. Antiviral properties of recombinant human lymphotoxin. Vopr Virusol 1995; 40:277-9.
4. Paya CV, Kenmotsu N, Schoon RA, Leibson PJ. Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. J Immunol 1988; 141:1989-95.
5. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med 1993; 177:763-74.
6. von Boehmer H. Lymphotoxins: from cytotoxicity to lymphoid organogenesis. Proc Natl Acad Sci USA 1997; 94:8926-7.
7. Miyake M, Horiuchi A, Kimura K, Abe Y, Kimura S, Hitsumoto Y. Correlation between killing activity towards the murine L929 cell line and expression of membrane-associated lymphotoxin-related molecule of human lymphokine-activated killer cells. Eur J Immunol 1992; 22:2147-52.
8. Medvedev AE, Espevik T, Ranges G, Sundan A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 1996; 271:9778-84.
9. Li DH, Havell EA, Brown CL, Cullen JM. Woodchuck lymphotoxin-alpha, -beta and tumor necrosis factor genes: structure, characterization and biological activity. Gene 2000; 242:295-305.
10. Mikami T, Uozumi T, Kurisu K, Kawamoto K, Kiya K, Hotta T. In vivo effects of recombinant human lymphotoxin on human medulloblastoma xenograft: enhancement of antitumor activity of etoposide. Biotherapy 1994; 8:7-17.
11. Sysoeva GM, Fadina VA, Popova NA, Nikitenko EV, Nikolin VP, Il'nitskaya SI, Kaledin VI. Potentiation of antitumor effects of cisplatin by tumor necrosis factor-beta .Bull Exp Biol Med 2001; 131:159-61.
12. Wallach D, Boldin M, Goncharov T, Goltsev Y, Mett I, Malinin N, Adar R, Kovalenko A, Varfolomeev E. Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Behring Inst Mitt 1996; 97:144-55.
13. Haviv R, Stein R. The intracellular domain of p55 tumor necrosis factor receptor induces apoptosis which requires different caspases in naive and neuronal PC12 cells. J Neurosci Res 1998; 52:380-9.
14. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-67.
15. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci USA 1996; 93:13973-8.
16. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NFkappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-3.
17. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300-4.
18. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17:2215-23.
19. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NFkappaB-dependent XIAP upregulation. J Biol Chem 2004; 279:24015-23.
20. Kim HS, Kim S, Lee MS. IFNgamma sensitizes MIN6N8 insulinoma cells to TNFalpha-induced apoptosis by inhibiting NFkappaB-mediated XIAP upregulation. Biochem Biophys Res Commun 2005; 336:847-53.
21. Barkett M, Gilmore TD. Control of apoptosis by Rel/NFkappaB transcription factors. Oncogene 1999; 18:6910-24.
22. Karin M, Lin A. NFkappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-7.
23. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376:37-43.
24. Na S, Chuang TH, Cunningham A, Turi TG, Hanke JH, Bokoch GM, Danley DE. D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis. J Biol Chem 1996; 271:11209-13.
25. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, Leung DW, Moffat B, Ng P, Svedersky LP, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312:721-4.
26. Wang FH, Li YH, Li S, Jiang WQ, Guan ZZ. Phase I clinical trial of intravenous recombinant human lymphotoxin-alpha derivative [Article in Chinese]. Ai Zheng 2006; 25:501-4.
27. Hellerstedt BA, Pienta KJ. Testicular cancer. Curr Opin Oncol 2002; 14:260-4.
28. Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep 2001; 3:147-55.
29. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001; 12:1195-203.
30. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-7.
31. Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17:2763-9.
32. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995; 34:8474-80.
33. Martin SJ, Cotter TG. Disruption of microtubules induces an endogenous suicide pathway in human leukaemia HL-60 cells. Cell Tissue Kinet 1990; 23:545-59.
34. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factorkappaB activation in human melanoma cells. Cancer Res 2001; 61:4901-9.
35. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res 2001; 61:3810-8.
36. Ear T, Cloutier A, McDonald PP. Constitutive nuclear expression of the IkappaB kinase complex and its activation in human neutrophils. J Immunol 2005; 175:1834-42.
37. Mayo MW, Baldwin AS. The transcription factor NFkappaB: control of oncogenesis and cancer therapy resistance. AS Biochim Biophys Acta 2000; 1470:55-62.
38. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NFkappaB. J Clin Invest 2001; 107:241-6.
39. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NFkappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000; 119:1209-18.
40. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-9.
41. Yamamoto Y, Gaynor RB. Role of the NFkappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001; 1:287-96.
42. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG, Tsang BK. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 2001; 142:370-80.
43. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999; 6:99-104.